medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2006, Number 06

<< Back Next >>

Ginecol Obstet Mex 2006; 74 (06)

Present usefulness of diagnostic tests in hyperandro-genism

Estuardo LI, Hernández MI, Ayala RA

Language: Spanish
References: 17
Page: 327-333
PDF size: 386.10 Kb.


ABSTRACT

There are diagnostic tests that allow to differentiate feminine hyperandrogenism of tumorous, non-tumorous, ovarian, adrenal and peripheral origin. We made a review of the current available tests accordingly to a case of amenorrhea and hyperandrogenism. By means of the low-dose dexamethasone suppression and human chorionic gonadotropin hormone (hCG) stimulation test we confirmed a suprarenal participation. There was spontaneous menses when treated with dexamethasone.


REFERENCES

  1. Ayala RA. Etiología y fisiopatología de la virilización. Ginecol Obstet Mex 1980;48:425-8.

  2. 2. Kirschner MA, Jacobs JB. Combined ovarian and adrenal vein catheterization to determine the site(s) of androgen overproduction in hirsute women. J Clin Endocrinol Metab 1971;33:199-209.

  3. Rosenfield RL, Lucky AW, Ehrmann DA, Barnes RB, Sheikh Z. Acne, hirsutism, and alopecia in adolescent girls. Clinical expressions of androgen excess. Endocrinol Metab Clin North Am 1193;22:507-32.

  4. Rittmaster RS, Kaltsas TJ, Cunningham S, McCabe M, Culliton M. Hirsutism. Lancet 1997;349:191-5.

  5. Abraham GE, Maroulis GB, Buster JE, Chang RJ, Marshall JR. Effect of dexamethasone on serum cortisol and androgen levels in hirsute patients. Obstet Gynecol 1976;47:395-402.

  6. Abraham GE, Maroulis GB, Boyers SP, Buster JE, Magyar DM, et al. Dexamethasone suppression test in the management of hyperandrogenized patients. Obstet Gynecol 1981;57:158-65.

  7. O’Driscoll JB, Mamtora H, Higginson J, Pollock A, et al. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf) 1994;41:231-6.

  8. Rosenfield RL, Ehrmann DA, Barnes RB, Sheikh Z. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann NY Acad Sci 1993;687:162-81.

  9. Rosenfield RL, Newell P, Trainere P, Besser M, et al. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:265-293.

  10. Hernández I, Ayala A, Carrera E. Lienzos de reproducción humana. México: Editores de Textos Mexicanos, 2004;pp:3-15.

  11. Waggoner W, Boots LR, Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study. Gynecol Endocrinol 1999;13:394-400.

  12. Adashi EY, Rosenwaks Z, Lee PA, Jones GS, Migeon CJ. Endocrine features of an adrenal-like tumor of the ovary. J Clin Endocrinol Metab 1979;48:241-5.

  13. Azizlerli H, Tanakol R, Terzioglu T, Alagol F, Dizdaroglu F. Steroid cell tumor of the ovary as a rare cause of virilization. Mt Sinai J Med 1997;64:130-5.

  14. Chrousos GP, Detera-Wadleigh SD, Karl M. Syndromes of glucocorticoid resistance. Ann Intern Med 1993;119:1113-24.

  15. Derksen J, Nagesser SK, Meinders AE, Haak HR, van de Velde CJ. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994;331:968-73.

  16. Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5-[alpha]-reductase activity in polycystic ovary syndrome. Lancet 1990;335:431-3.

  17. Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 [beta]-hydroxysteroid dehydrogenase. N Engl J Med 1994;330:460-5.




2020     |     www.medigraphic.com